Ignite Creation Date:
2025-12-24 @ 7:55 PM
Ignite Modification Date:
2025-12-27 @ 11:27 AM
Study NCT ID:
NCT05574504
Status:
WITHDRAWN
Last Update Posted:
2024-08-01
First Post:
2022-09-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy
Sponsor:
AdventHealth
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-05-08
Start Date Type:
ACTUAL
Primary Completion Date:
2026-11
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-11
Completion Date Type:
ESTIMATED
First Submit Date:
2022-09-19
First Submit QC Date:
None
Study First Post Date:
2022-10-10
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-07-31
Last Update Post Date:
2024-08-01
Last Update Post Date Type:
ACTUAL